Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

SPIRIT IV, 2010 - everolimus ES vs paclitaxel ES

SORT-OUT-3, 2010 - zotarolimus ES vs sirolimus ES

ISAR-DESIRE-2, 2010 - sirolimus ES vs paclitaxel ES

RESOLUTE, 2010 - zotarolimus ES vs everolimus ES

ZEST (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

PASEO, 2009 - drug ES vs bare-metal stent

Thiele, 2009 - sirolimus ES vs MIDCAB

ISAR TEST 2 (vs ZES), 2009 - dual sirolimus, probucol ES vs zotarolimus ES

ISAR TEST 3 (PF), 2009 - polymer free sirolimus stent vs sirolimus ES

ENDEAVOR IV, 2009 - zotarolimus ES vs paclitaxel ES

GENIUS-STEMI, 2009 - Genous stent vs bare-metal stent

ZEST AMI (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

STICH (ventricular reconstruction), 2009 - CABG+surgical ventricular reconstruction vs CABG

ISAR TEST 2 (vs SES), 2009 - dual sirolimus, probucol ES vs sirolimus ES

COMPARE, 2009 - everolimus ES vs paclitaxel ES

ISAR TEST 3 (BP), 2009 - biodegradable-polymer sirolimus stent vs sirolimus ES

ZEST (vs SES), 2009 - zotarolimus ES vs sirolimus ES

ZEST AMI (vs SES), 2009 - zotarolimus ES vs sirolimus ES

BARI 2D, 2009 - CABG or PCI vs medical treatment

DEBATER (SES vs BMS), 2009 - sirolimus ES vs bare-metal stent

ISAR-TEST-4, 2009 - sirolimus biodegradable polymer vs sirolimus ES

SYNTAX, 2009 - paclitaxel ES vs CABG

ISAR-LEFT-MAIN, 2009 - sirolimus ES vs paclitaxel ES

Kim, 2008 - sirolimus ES vs paclitaxel ES

MISSION, 2008 - sirolimus ES vs bare-metal stent



See also:

  • All coronary artery disease clinical trials
  • All stable angina clinical trials
  • All clinical trials of revascularization with drug eluting stent
  • All clinical trials of sirolimus ES
    		•  

    Han study, 2006

    Treatments

    Studied treatment Cypher
    Control treatment Taxus

    Patients

    Patients Multivessel disease. Stable or unstable AP, no AMI
    Baseline characteristics
    age NA 
    diabetes (%) NA 
    Lesion diameter inclusion criteria NA 
    Female (%) NA 

    Method and design

    Randomized effectives 210 / 206 (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration 19.5 months (mean)
    Number of centre NA
    Geographic area China
    Primary endpoint none


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    All cause death

    3 / 210
         4 / 206
         classic 0,74 [0,17;3,25]

    MI (fatal and non fatal)

    2 / 210
         3 / 206
         classic 0,65 [0,11;3,87]

    target lesion revascularisation

    9 / 210
         11 / 206
         0,80 [0,34;1,90]

    4y stent thrombosis (ARC)

    1 / 210
         2 / 206
         classic 0,49 [0,04;5,37]

    Stent thrombosis (any, end of follow up)

    1 / 210
         2 / 206
         classic 0,49 [0,04;5,37]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    All cause death 3 / 210 (1,4%) 4 / 206 (1,9%) 0,74 [0,17;3,25]    
    MI (fatal and non fatal) 2 / 210 (1,0%) 3 / 206 (1,5%) 0,65 [0,11;3,87]    
    Stent thrombosis (any, end of follow up) 1 / 210 (0,5%) 2 / 206 (1,0%) 0,49 [0,04;5,37]    
    4y stent thrombosis (ARC) 1 / 210 (0,5%) 2 / 206 (1,0%) 0,49 [0,04;5,37]    
    target lesion revascularisation 9 / 210 (4,3%) 11 / 206 (5,3%) 0,80 [0,34;1,90]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    All cause death 1,43% 1,94% -5,1‰
    MI (fatal and non fatal) 9,52‰ 1,46% -5,0‰
    Stent thrombosis (any, end of follow up) 4,76‰ 9,71‰ -4,9‰
    4y stent thrombosis (ARC) 4,76‰ 9,71‰ -4,9‰
    target lesion revascularisation 4,29% 5,34% -10,5‰


    Reference(s)

    Trials register # NA
    • Han YL, Wang XZ, Jing QM, Wang SL, Ma YY, Luan B. [Comparison of Rapamycin and Paclitaxel eluting stent in patients with multi-vessel coronary disease]. Zhonghua Xin Xue Guan Bing Za Zhi 2006;34:123-6
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend